Exelixis, Inc.
EXEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000939767
In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Exelixis, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $526.5K in total
- Insiders trading
- 1
- Net value
- −$526.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Exelixis, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Beckerle Mary C | Director | 16,079 | Aug 12, 2026 | 4 |
| Wyszomierski Jack L | Director | 284,384 | Jun 3, 2026 | 3 |
| Eckhardt Sue Gail | Director | 16,079 | Jun 3, 2026 | 3 |
| Caligan Partners LP | Director, Other: See Remarks | 1,553,262Indirect | May 29, 2026 | 2 |
| Johnson David Edward | Director | 1,553,262Indirect | May 29, 2026 | 2 |
| Poste George | Director | 127,199 | May 29, 2026 | 2 |
| Papadopoulos Stelios | Director | 1,197,595 | May 29, 2026 | 2 |
| Freire Maria C | Director | 109,186 | May 29, 2026 | 2 |
| Smith Julie | Director | 28,957 | May 29, 2026 | 2 |
| Oliver Bob | Director | 29,487 | May 29, 2026 | 3 |
| Heyman Tomas J. | Director | 50,649 | May 29, 2026 | 1 |
| Aftab Dana | EVP, Research and Development | 594,741 | May 28, 2026 | 10 |
| Haley Patrick J. | EVP, Commercial | 357,638 | May 22, 2026 | 6 |
| Morrissey Michael | President and CEO | 2,004,327Indirect | May 19, 2026 | 6 |
| Senner Christopher J. | EVP and CFO | 952,317 | May 19, 2026 | 4 |
| Hefti Brenda | SVP and General Counsel | 106,762 | May 19, 2026 | 4 |
| Hessekiel Jeffrey | EVP & General Counsel | 693,396 | May 16, 2025 | 0 |
| Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | 465,393 | May 16, 2025 | 0 |
| Garber Alan M | Director | 35,703 | Mar 25, 2024 | 0 |
| Wright Jacqueline | Director | 51,756 | Jun 2, 2023 | 0 |
| Goodman Vicki L | EVP, Prod Dev & Med Aff &CMO | 307,654 | Apr 5, 2023 | 0 |
| Feldbaum Carl B | Director | 18,701 | Feb 10, 2023 | 0 |
| Lamb Peter | EVP, Scientific Strategy & CSO | 410,958 | Dec 16, 2022 | 0 |
| Marchesi Vincent T | Director | 93,989 | May 27, 2022 | 0 |
| Willsey Lance | Director | 424,415 | May 27, 2022 | 0 |
| Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | 689,078 | Jul 28, 2021 | 0 |
| Cohen Charles | Director | 261,375 | Jul 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 (view filing) | Feb 13-17 | 5 days | Senner Christopher J.EVP and CFO | SSale | −64.9K | $43.32 | −$2.81M | −6.2%976.1K after | 2 lots |
| Feb 19, 2026 (view filing) | Feb 17-18 | 2 days | Smith JulieDirector | SSale | −106.5K | $44.00 | −$4.69M | −83.8%20.6K after | 3 lots |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Wyszomierski Jack LDirector | SSale | −99.6K | $44.01 | −$4.38M | −26.2%279.9K after | 10b5-1 |
| Feb 23, 2026 (view filing) | Feb 19 | 4 days | Aftab DanaEVP, Research and Development | SSale | −29.9K | $44.35 | −$1.32M | −4.3%664.0K after | |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Aftab DanaEVP, Research and Development | SSale | −47.9K | $44.50 | −$2.13M | −7.2%616.1K after | |
| May 8, 2026 (view filing) | May 7 | 1 day | Poste GeorgeDirector | SSale | −60.0K | $45.71 | −$2.74M | −33.6%118.8K after | |
| May 8, 2026 (view filing) | May 7 | 1 day | Freire Maria CDirector | SSale | −20.6K | $46.00 | −$949.2K | −17.0%100.8K after | |
| May 8, 2026 (view filing) | May 7 | 1 day | Beckerle Mary CDirector | SSale | −7.71K | $48.45 | −$373.6K | −30.6%17.5K after | |
| May 19, 2026 (view filing) | May 18 | 1 day | Hefti BrendaSVP and General Counsel | SSale | −6.63K | $50.21 | −$332.6K | −5.8%106.8K after | 10b5-1 |
| May 19, 2026 (view filing) | May 18 | 1 day | Senner Christopher J.EVP and CFO | SSale | −34.9K | $50.00 | −$1.75M | −3.5%952.3K after | |
| May 22, 2026 (view filing) | May 20 | 2 days | Haley Patrick J.EVP, Commercial | SSale | −32.1K | $49.81 | −$1.60M | −8.2%357.6K after | |
| May 28, 2026 (view filing) | May 26 | 2 days | Aftab DanaEVP, Research and Development | SSale | −43.5K | $50.35 | −$2.19M | −6.8%594.7K after | |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Eckhardt Sue GailDirector | SSale | −9.81K | $50.14 | −$492.0K | −37.9%16.1K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Wyszomierski Jack LDirector | SSale | −3.92K | $50.55 | −$198.4K | −1.4%284.4K after | 10b5-1 |
| Aug 12, 2026 (view filing)7:34 PM ET | Aug 10 | 2 days | Beckerle Mary CDirector | SSale | −9.81K | $53.66 | −$526.5K | −37.9%16.1K after | 10b5-1 |